This government is making the most of our new found freedom to reform, repeal and replace outdated retained EU law that does not serve the interests of the UK. We are creating a regulatory environment which will promote growth, innovation and prosperity, cutting at least £1 billion of red tape for businesses, while maintaining the high standards the British people rightly expect.<\/p>
Cabinet Office is leading and coordinating the programme of work being undertaken by Secretaries of State across government, to identify and deliver the regulatory and economic opportunities that Brexit has provided. No staff within the Brexit Opportunities Unit in the Cabinet Office monitor how the EU chooses to diverge from the UK.<\/p>
The Government monitors significant EU policy developments that are likely to affect UK interests, to ensure compliance with the Trade and Cooperation Agreement and support business readiness as necessary. My officials and I undertake regular engagement with the Devolved Administrations on the opportunities arising from leaving the EU, using Common Frameworks and other existing intergovernmental structures.<\/p>
<\/strong> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4099", "label" : {"_value" : "Biography information for Sir Jacob Rees-Mogg"}
}
, "answeringMemberConstituency" : {"_value" : "North East Somerset"}
, "answeringMemberPrinted" : {"_value" : "Mr Jacob Rees-Mogg"}
, "dateOfAnswer" : {"_value" : "2022-06-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "11559"}
, {"_value" : "11561"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2022-06-08T17:17:51.8Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "53"}
, "answeringDeptShortName" : {"_value" : "Cabinet Office"}
, "answeringDeptSortName" : {"_value" : "Cabinet Office"}
, "date" : {"_value" : "2022-06-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "EU Law"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Minister for the Cabinet Office, how his Department (a) reviews EU developments and new regulations, (b) assesses the potential effect of UK divergence from those regulations on (i) UK industry, (ii) trade barriers between Great Britain and Northern Ireland, (iii) devolved administrations, (iv) level playing field provisions in the UK-EU Trade and Cooperation Agreement and EU adequacy and equivalence decisions and (v) levels of protection for the environment, labour and human health and (c) makes assessments as to which regulations the UK should align with and where there may be potential opportunities from divergence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/413", "label" : {"_value" : "Biography information for Hilary Benn"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds Central"}
, "tablingMemberPrinted" : [{"_value" : "Hilary Benn"}
], "uin" : "11560"}
, {"_about" : "http://data.parliament.uk/resources/1330117", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1330117/answer", "answerText" : {"_value" : " The Department has discussed the role of brain tumour experts with the National Institute for Health Research. There have been no discussions on patient advocates as all committees include public members who bring the patient and public perspective to discussions.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
}
, "answeringMemberConstituency" : {"_value" : "Charnwood"}
, "answeringMemberPrinted" : {"_value" : "Edward Argar"}
, "dateOfAnswer" : {"_value" : "2021-06-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-06-21T09:01:07.68Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-06-07", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Brain: Tumours"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with representatives of the National Institute for Health Research (NIHR) on including brain tumour (a) experts and (b) patient advocates on the NIHR panel that considers brain tumour research proposals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4253", "label" : {"_value" : "Biography information for Seema Malhotra"}
}
, "tablingMemberConstituency" : {"_value" : "Feltham and Heston"}
, "tablingMemberPrinted" : [{"_value" : "Seema Malhotra"}
], "uin" : "11560"}
, {"_about" : "http://data.parliament.uk/resources/1175558", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1175558/answer", "answerText" : {"_value" : " The Department does not centrally collect data surrounding the volume of Universal Credit claimants who have had claims restricted or rejected because of relevant period regulations.<\/p> <\/p> For those who claim Universal Credit on health grounds, we generally determine if the claimant has limited capability for work (LCW), limited capability for work and work related activity (LCWRA) or is fit for work, based on the advice given by the Centre for Health and Disability Assessments\u2019 health care professional who carried out the claimant\u2019s work capability assessment (WCA).<\/p> <\/p> Where the claimant is determined to have LCWRA, an additional amount of benefit may be awarded. This additional amount will be included in the Universal Credit award from the first full assessment period after the 3 month relevant period ends.<\/p> <\/p> The 3 month relevant period in Universal Credit mirrors the 13-week assessment phase in Employment and Support Allowance and is used, in both benefits, to establish whether the claimant has a long-term health condition or a short term illness, and also ensures a consistent date of application, as there may be fluctuations in times taken to process and apply a decision following a WCA.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4105", "label" : {"_value" : "Biography information for Justin Tomlinson"}
}
, "answeringMemberConstituency" : {"_value" : "North Swindon"}
, "answeringMemberPrinted" : {"_value" : "Justin Tomlinson"}
, "dateOfAnswer" : {"_value" : "2020-02-11", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "11559"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2020-02-11T10:55:21.82Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "29"}
, "answeringDeptShortName" : {"_value" : "Work and Pensions"}
, "answeringDeptSortName" : {"_value" : "Work and Pensions"}
, "date" : {"_value" : "2020-02-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Universal Credit"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Work and Pensions, how many universal credit claimants have had claims restricted or rejected because of relevant period regulations in (a) 2017, (b) 2018 and (c) 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4515", "label" : {"_value" : "Biography information for Kate Osamor"}
}
, "tablingMemberConstituency" : {"_value" : "Edmonton"}
, "tablingMemberPrinted" : [{"_value" : "Kate Osamor"}
], "uin" : "11560"}
, {"_about" : "http://data.parliament.uk/resources/421099", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/421099/answer", "answerText" : {"_value" : " NHS England has received 12 letters from hon. Members and has met with key stakeholders, including patient organisations and charities such as the Royal National Institute of Blind People and Olivia\u2019s Vision. This followed their decision in July not to fund Infliximab (Remicade) and Adalimumab (Humira), Anti-TNF drugs, as a treatment for adults and children with severe refractory uveitis.<\/p> NHS England has also been in discussion with Abbvie, a Pharmaceutical Research and Development Company which is due to report on their trial of Adalimumab in adults in early 2016.<\/p> The National Institute for Health and Care Excellence (NICE) is developing technology appraisal guidance on the use of the drugs dexamethasone and sorolimus for the treatment of uveitis. NICE develops its technology appraisal guidance in consultation with a broad range of stakeholders and the representations it receives in the development of its guidance will be available on the NICE website at:<\/p>
<\/p>